Lv41
600 积分 2025-06-04 加入
Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel
14天前
已完结
Prognostic value of tumor dissemination feature based on baseline 18F-FDG PET/CT in patients with newly diagnosed multiple myeloma
23天前
已完结
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
1个月前
已完结
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
1个月前
已完结
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial
1个月前
已完结
Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse
1个月前
已完结
Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML
1个月前
已完结
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial
2个月前
已完结
Outcomes of Triple-Class Refractory Multiple Myeloma Patients at a Single Clinic: A Retrospective Study
2个月前
已完结
Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety
2个月前
已完结
皖公网安备34019202002308
